Last week, the FDA approved Addyi® (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women. Let that sink in. For decades, postmenopausal women were excluded from FDA-approved options for low desire—despite real distress, real relationships, and real quality-of-life impact. That changes now. 🎙️ On this week’s episode of You Are Not Broken, I break down: • What this approval actually means (and what it doesn’t) • How long it took medicine to take women